Köktürk Uğur, Püşüroğlu Hamdi, Somuncu Mustafa Umut, Akgül Özgür, Uygur Begüm, Özyılmaz Sinem, Işıksaçan Nilgün, Sürgit Özgür, Yıldırım Aydın
Department of Cardiology, Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Center, Training and Research Hospital, Istanbul, Turkey.
Department of Biochemistry, Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Center, Training and Research Hospital, Istanbul, Turkey.
Angiology. 2023 Oct;74(9):889-896. doi: 10.1177/00033197221149846. Epub 2023 Jan 3.
This study evaluated the short and long-term prognostic value of galectin-3 in patients with ST-segment elevation myocardial infarction (STEMI) who underwent primary percutaneous coronary intervention (PCI). Patients (n = 143) were admitted with STEMI and followed up for 2 years. The study population was divided into high and low galectin-3 groups based on the admission median value of serum galectin-3. Primary clinical outcomes consisted of cardiovascular (CV) mortality, non-fatal reinfarction, stroke, and target vessel revascularization (TVR). CV events were recorded in hospital and at 1 and 2 years. The primary clinical outcomes (in-hospital, 1 year and 2 year) were significantly higher in the high galectin-3 group. ( = .008, = .004, = .002, respectively). High galectin-3 levels were also associated with heart failure development and re-hospitalization at both 1 year ( = .029, = .009, respectively) and 2 years ( = .019, = .036, respectively). According to Cox multivariate analysis, left ventricular ejection fraction (LVEF) was an independent predictor of 2-year cardiovascular mortality ( = .009), whereas galectin-3 was not ( = .291). Although high galectin-3 levels were not independent predictors of long-term CV mortality in patients with acute STEMI who underwent primary PCI, it was associated with short-term and long-term development of adverse CV events, heart failure, and re-hospitalization.
本研究评估了半乳糖凝集素-3在接受直接经皮冠状动脉介入治疗（PCI）的ST段抬高型心肌梗死（STEMI）患者中的短期和长期预后价值。143例患者因STEMI入院，并随访2年。根据血清半乳糖凝集素-3入院中位值将研究人群分为高半乳糖凝集素-3组和低半乳糖凝集素-3组。主要临床结局包括心血管（CV）死亡率、非致命性再梗死、中风和靶血管血运重建（TVR）。记录住院期间以及1年和2年时的CV事件。高半乳糖凝集素-3组的主要临床结局（住院期间、1年和2年）显著更高（分别为P = 0.008、P = 0.004、P = 0.002）。高半乳糖凝集素-3水平还与1年（分别为P = 0.029、P = 0.009）和2年（分别为P = 0.019、P = 0.036）时的心力衰竭发生和再次住院相关。根据Cox多因素分析，左心室射血分数（LVEF）是2年心血管死亡率的独立预测因素（P = 0.009），而半乳糖凝集素-3不是（P = 0.291）。虽然高半乳糖凝集素-3水平不是接受直接PCI的急性STEMI患者长期CV死亡率的独立预测因素，但它与不良CV事件、心力衰竭和再次住院的短期和长期发生相关。
